Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBC1 domain family member 3L (TBC1D3L) is a member of the TBC (Tre-2, Bub2, Cdc16) domain family, which largely functions as regulatory proteins in intracellular vesicle trafficking and cell signaling. TBC1D3L is part of a hominoid-specific gene family with several paralogs arrayed on chromosome 17, and is predicted to act as a GTPase activating protein (GAP) for the small GTPase RAB5, regulating endocytosis and trafficking of surface receptors such as EGFR, though it appears to lack classic GAP activity due to a missing catalytic residue[3][4]. Through these functions, TBC1D3 family members—including TBC1D3L—may alter the payload and secretion of extracellular vesicles, influence growth factor receptor signaling, and modulate cell proliferation. Dysregulation or overexpression of TBC1D3 paralogs has been associated with several cancers and altered immune microenvironments[1][2][6]. Despite research highlighting its influence on cancer cell signaling pathways and immune modulation, there are no approved drugs that directly target TBC1D3L, and its current status is best categorized as a biomarker or candidate of mechanistic interest rather than a validated therapeutic target. Notes on correctness: - The entity "TBC1 domain family member 3L" (TBC1D3L) is a valid protein-coding gene, but documentation about this specific paralog (as opposed to TBC1D3 generally) is sparse, and functions are often inferred from the broader TBC1D3 family[4][6]. - No evidence currently supports its classification as a direct therapeutic target (e.g., receptor, enzyme, transporter). - No drugs are known to directly interact with it, and mechanisms of action pertain to cellular pathway modulation, not targeted pharmacology. If information specifically about TBC1D3L (rather than the entire TBC1D3 gene family) is required, data are incomplete due to high sequence similarity and overlapping function among the paralogs. The most robust evidence concerns TBC1D3 as a family, not TBC1D3L individually[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBC1 domain family member 3L (TBC1D3L).